Announcements
- IGM Biosciences Announces Refocusing of Sanofi Collaboration
- IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
- IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
- IGM Biosciences Announces Third Quarter 2023 Financial Results
- IGM Biosciences to Present at Two Upcoming Investor Conferences
- IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
- IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
More ▼
Key statistics
On Tuesday, IGM Biosciences Inc (1K0:DUS) closed at 8.95, -5.29% below its post-IPO high of 9.45, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.95 |
---|---|
High | 8.95 |
Low | 8.95 |
Bid | 8.90 |
Offer | 9.10 |
Previous close | 9.45 |
Average volume | 50.00 |
---|---|
Shares outstanding | 58.79m |
Free float | 21.47m |
P/E (TTM) | -- |
Market cap | 570.23m USD |
EPS (TTM) | -4.81 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 18:30 BST.
More ▼